Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase

Abl kinase inhibitors targeting the ATP binding pocket are currently employed as potent anti-leukemogenic agents but drug resistance has become a significant clinical limitation. Recently, a compound that binds to the myristate pocket of Abl (GNF-5) was shown to act cooperatively with nilotinib, an ATP-competitive inhibitor to target the recalcitrant “T315I” gatekeeper mutant of Bcr-Abl. To uncover an explanation for how drug binding at a distance from the kinase active site could lead to inhibition and how inhibitors could combine their effects, hydrogen exchange mass spectrometry (HX MS) was employed to monitor conformational effects in the presence of both dasatinib, a clinically approved ATP-site inhibitor, and GNF-5. While dasatinib binding to wild type Abl clearly influenced Abl conformation, no binding was detected between dasatinib and T315I. GNF-5, however, elicited the same conformational changes in both wild type and T315I, including changes to dynamics within the ATP site located approximately 25 Å from the site of GNF-5 interaction. Simultaneous binding of dasatinib and GNF-5 to T315I caused conformational and/or dynamics changes in Abl such that effects of dasatinib on T315I were the same as when it bound to wild type Abl. These results provide strong biophysical evidence that allosteric interactions play a role in Abl kinase downregulation and that targeting sites outside the ATP binding site can provide an important pharmacological tool to overcome mutations that cause resistance to ATP-competitive inhibitors.

[1]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[2]  Jorge Cortes,et al.  Flying under the radar: the new wave of BCR–ABL inhibitors , 2007, Nature Reviews Drug Discovery.

[3]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[4]  J. Mestan,et al.  Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.

[5]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[6]  Ping Chen,et al.  2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase in , 2006, Journal of medicinal chemistry.

[7]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[8]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[9]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[10]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[11]  Christopher R. Morgan,et al.  Investigating Solution‐Phase Protein Structure and Dynamics by Hydrogen Exchange Mass Spectrometry , 2009, Current protocols in protein science.

[12]  Gennady M Verkhivker.  In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. , 2007, Biopolymers.

[13]  Stephen K Burley,et al.  SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib , 2008, Proceedings of the National Academy of Sciences.

[14]  Oliver Hantschel,et al.  Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.

[15]  John R Engen,et al.  High-speed and high-resolution UPLC separation at zero degrees Celsius. , 2008, Analytical chemistry.

[16]  G. Daley,et al.  9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. , 2009, Journal of medicinal chemistry.

[17]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[18]  John Kuriyan,et al.  Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. , 2009, Cancer research.

[19]  T. Wales,et al.  Hydrogen exchange mass spectrometry for the analysis of protein dynamics. , 2006, Mass spectrometry reviews.

[20]  John R. Engen,et al.  Conformational disturbance in Abl kinase upon mutation and deregulation , 2009, Proceedings of the National Academy of Sciences.

[21]  H. Kantarjian,et al.  Novel tyrosine kinase inhibitors in chronic myelogenous leukemia , 2006, Current opinion in oncology.

[22]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[23]  Daniel K. Treiber,et al.  Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. , 2006, Cancer research.

[24]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[25]  N. Gray,et al.  N-Myristoylated c-Abl Tyrosine Kinase Localizes to the Endoplasmic Reticulum upon Binding to an Allosteric Inhibitor* , 2009, The Journal of Biological Chemistry.

[26]  D. Smith,et al.  Mass spectrometric determination of isotopic exchange rates of amide hydrogens located on the surfaces of proteins. , 1996, Analytical chemistry.

[27]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[28]  Nathanael Gray,et al.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.

[29]  T. Zhou,et al.  Crystal Structure of the T315I Mutant of Abl Kinase , 2007, Chemical biology & drug design.

[30]  N. Kallenbach,et al.  Hydrogen exchange and structural dynamics of proteins and nucleic acids , 1983, Quarterly Reviews of Biophysics.

[31]  L. Scapozza,et al.  In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. , 2006, Cancer research.

[32]  G. Noronha,et al.  Inhibitors of ABL and the ABL-T315I mutation. , 2008, Current topics in medicinal chemistry.

[33]  J. Kuriyan,et al.  High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases , 2005, Protein science : a publication of the Protein Society.

[34]  H. Kantarjian,et al.  Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. , 2005, Current molecular medicine.

[35]  John Kuriyan,et al.  Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.

[36]  James D. Griffin,et al.  Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. , 2010, Blood.

[37]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[38]  J. R. Engen,et al.  Semi-automated data processing of hydrogen exchange mass spectra using HX-Express , 2006, Journal of the American Society for Mass Spectrometry.

[39]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[40]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[41]  E. Reddy,et al.  Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[42]  I. Wilson,et al.  UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. , 2006, Rapid communications in mass spectrometry : RCM.

[43]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[44]  A. Kornberg,et al.  Di- and triphosphopyridine nucleotide isocitric dehydrogenases in yeast. , 1951, The Journal of biological chemistry.

[45]  Wolfgang Jahnke,et al.  Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib*♦ , 2008, Journal of Biological Chemistry.

[46]  Antonella Isacchi,et al.  Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. , 2007, Cancer research.